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ABSTRACT
Background: Environmental enteric dysfunction (EED)
is an asymptomatic intestinal disorder affecting
populations living in conditions of poor sanitation and
hygiene. The study tested intestinal barrier function in
infants with EED.
Methods: We prospectively studied an advanced high-
performance liquid chromatography mass spectrometry
assay of urine collected after oral intake of the
monosaccharide, L-rhamnose and the disaccharide,
lactulose, in 112 children from three continents.
Findings: Compared to the US cohort (n=27), the
cohorts of children from Peru (n=19) and Zambia
(n=85) were older with evidence of growth impairment.
The median (range) of age (months) was 8.0 (2.0 to
13.0), 27.0 (15.0 to 29.0) and 21.0 (12.0 to 36.0),
respectively. The median (range) of height for age Z
score was −0.1 (−1.8 to 2.4), −1.8 (−3.3 to −0.2) and
−2.3 (−8.5 to 1.2), respectively. Among children with
valid sugar data (n=22 USA, n=19 Peru, n=73 Zambia),
there were no significant differences in the median
rhamnose urine concentrations between the three
groups. The median (range) lactulose concentration
(µg/mL) was 6.78 (0.29 to 31.90), 47.60 (4.23 to
379.00) and 75.40 (0.67 to 873.00) in the US, Peruvian
and Zambian cohorts, respectively (p<0.001). The
lactulose/rhamnose ratio (LRR) was higher in cohorts
from Peru (0.75, 0.15, 5.02) and Zambia (2.26, 0.08,
14.48) compared to the US (0.14, 0.06, 1.00) cohort
(p<0.001). In a multivariate effect modification model,
higher weight-for-age z scores were associated with
lower post-dose lactulose when rhamnose excretion
was constant (p=0.003).
Conclusions: This non-invasive two saccharide
permeability protocol measures changes in intestinal
permeability in children with EED and permits the
identification of individuals for interventional trials.
INTRODUCTION
Environmental enteric dysfunction (EED) is
a disorder of the small bowel affecting
populations living in conditions of poor sani-
tation and hygiene.1 It is hypothesised that
repetitive intestinal infection results in
chronic intestinal inflammation, villous
Key questions
What is already known about this topic?
▸ Environmental enteric dysfunction (EED) is a
disorder of the small bowel affecting populations
living in conditions of poor sanitation and
hygiene.
▸ EED leads to chronic malnutrition and stunting,
which affects 26% of children <5 years of age in
the developing world and leads to 21% of
deaths in this age group.
▸ There is a critical need for a reliable, simple,
non-invasive and sensitive biomarker of disease
activity to potentially identify in the field high-
risk individuals who are candidates for interven-
tional trials.
▸ The current application of the lactulose/mannitol
assay inconsistently identifies at-risk or affected
patients from endemic populations.
What are the new findings?
▸ We demonstrate a novel method that refines the
saccharide intestinal permeability assay through
the choice of monosaccharide, the method of
detection, the timing of urine collection and the
dose of analytes.
▸ We provide normative values of the lactulose/
rhamnose permeability assay in healthy infants.
▸ We document evidence for increased intestinal
permeability in two cohorts of children from
populations in which EED is endemic.
▸ The method described has the potential to
provide consistent test performance in the field
for the detection of impaired intestinal barrier
integrity in EED and selection of patients for
therapeutic trials.
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atrophy, malabsorption and linear growth failure. EED is
a putative underlying cause of chronic malnutrition and
stunting, which affects 26% of children under 5 years of
age in the developing world and is associated with 21%
of deaths in this age group (http://www.un.org/
millenniumgoals). Poor nutrition is associated with cog-
nitive stunting with implications for future socio-
economic status.2 EED may also explain the reduced
efficacy of oral vaccines in low income and middle
income countries and the increased risk of serious infec-
tion in children with undernutrition.3 4 Thus, there is a
critical need for a reliable, simple, non-invasive and sen-
sitive biomarker of disease activity to potentially identify
in the field high-risk individuals who are candidates for
interventional trials.
Saccharide-based permeability assays (eg, lactulose/
mannitol) have been widely used in malabsorptive condi-
tions; however, the current application of the lactulose/
mannitol assay inconsistently identifies at-risk or affected
patients from endemic populations.5 Potential limitations
in test performance include the enzymatic method to
measure the saccharides, the timing of urine collection
and the test saccharides chosen. The standard 5-hour
urine collection period has led to the unclear relation-
ship between probe concentration and permeability of
different gastrointestinal (GI) tract segments. Finally,
since mannitol was identified at baseline (before oral
administration of the test sugar) among adults studied in
the USA in up to 30% of participants,6 significant con-
cerns exist regarding contributions to the analyte in the
collected sample by the same saccharide from non-probe
sources. The monosaccharide L-rhamnose is a hydro-
philic deoxy sugar of similar molecular weight and
volume (by van der Walls surface) as mannitol, but it is
less widely used in food and other materials and is there-
fore an alternative candidate for evaluation of malabsorp-
tion and intestinal permeability.
Our study aim was to address the principal limitations
of the current LM test and prospectively compare intes-
tinal barrier function in infants with EED from at-risk
populations on two continents (age below 37 months)
with healthy control infants (2–13 months of age) from
the USA. We describe a standardised method including
administration protocol, consistent urine collection
applicable at points of care in the field, and a reliable
assay that can be performed at a centralised laboratory
using liquid chromatography-mass spectrometry. The
sensitivity and accuracy of this analytical chemistry
approach has allowed our laboratory to reduce (by a
factor of 5) the administered doses of rhamnose and lac-
tulose, a change that both makes the test easier to toler-
ate and more likely to proceed without confounding by
major alterations of intestinal motility and transit.7
Furthermore, by shortening the time of urine collection,
the permeability deficits documented are more likely a
result of permeability in the small bowel where EED
changes are thought to occur and also make the test
easier to perform in the resource limited settings.
METHODS
Participants
Olmsted County, MN: Healthy infants between 2 and
13 months of age (n=27) were recruited from the out-
patient practice at Mayo Clinic, Olmsted County,
Minnesota, USA. These children were recruited at well-
child visits during routine preventative care (2, 4, 6, 9 and
12 months). Age (months), length (cm) and weight (kg)
were recorded. Additional metadata recorded included
the time of last oral intake, current medications or symp-
toms within previous 48 hours to the study visit.
Lusaka, Zambia: Children between 2 and 36 months
(n=85) were recruited from one sector of the Misisi
township in Lusaka, the capital of Zambia. Misisi com-
pound is a district of southern Lusaka in which studies
of EED have been conducted since 1999.8
Loreto, Peru: A second cohort (n=19) of patients
from an EED region (age range 15–29 months) was
recruited from three rural communities in the
Department of Loreto, 15 km southeast of Iquitos, Peru.
Studies of EED have been performed there since 2009.9
Eligibility criteria
Children with concurrent illness or who had had diar-
rhoea within 1 month, or who had been given antibiotics
within 1 month were excluded from study. Patients with
a positive stool sample for ova and parasites at least
7 days prior to the study received treatment prior to the
saccharide assay.
Ethical committee approval
Approval for the study was obtained from the University
of Zambia Biomedical Research Ethics Committee
(006-01-13, 11 April 2013) and the Institutional Review
Board of the John’s Hopkins Bloomberg School of Public
Health and the Ethics Committee of Asociacion Benefica
PRISMA in Lima, Peru.9 The study was approved by the
Mayo Clinic Institutional Review Board (12-003757,
approved 18 April 2012), and informed consent was
obtained by the parent(s) or legal guardian(s).
Key questions
Recommendations for policy
▸ We recommend the use of rhamnose over mannitol when per-
forming the saccharide intestinal permeability assay given the
significant environmental contamination of the latter.
▸ We recommend the reporting of both test analytes (over
simply a ratio), as saccharide intestinal absorption reflects
complex intestinal physiology related to both permeability and
loss of surface area.
▸ When using high-performance liquid chromatography with
tandem mass spectrometry as the saccharide quantification
methodology, a shortened 60–90 min urine collection window
may lead to a more focused evaluation of small bowel perme-
ability and enhanced test performance.
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Urine collection protocol
The clinical protocol including saccharide administra-
tion, timing of urine collection and anthropometric data
collection was identical across the three sites. The
reagents were purchased from TCI chemicals, Portland,
Oregon (USA and Peru) and Sigma-Aldrich, St Louis,
Missouri, USA (Zambia). Aliquots of frozen urine were
shipped on dry ice to the ICL at Mayo Clinic. Urine
samples were collected pre dosing and post dosing.
Administration of sugars
The oral solution consisted of 200 mg monosaccharide
(L-rhamnose, TCI product code R0013, Portland,
Oregon, USA) and 1000 mg disaccharide (lactulose, TCI
product code L0140 Portland, Oregon, USA) in 10 mL
sterile water. Study personnel administered the entire
solution over a period of 5 min to the infant.
Annotations were collected for notable issues during
dosing (infant spitting up, refusal, etc).
Post-dose urine collection
The urine bag was placed on the infant 30 min post
dosing and collected over the subsequent 60 min (30–
90 min post dosing). Oral intake (water, breast milk,
formula, no solid foods) after administration of sugar
solution was encouraged with a goal of 4 mL/kg intake
over 30 min to promote urine production. If no urine
was present at the end of 60 min, the collection was con-
tinued until urine was present in the bag but no longer
than an additional 30 min.
Samples were labelled with participant study ID and
with a pre-dose or post-dose tag. Samples were stored at
−20°C until analysis. Batched samples were placed on
dry ice and delivered to the Immunochemical Core
Laboratory (ICL) at Mayo Clinic for analysis.
Methodology of HPLC MS:MS
The methodology was performed as recently published
with the following modifications to account for the
molecular weight transition for rhamnose.6 The follow-
ing transitions were monitored: mannitol analyte
(181.05/89), 13C(6) mannitol IS (186.9/60.9), lactulose
analyte (341/101) 13C(12) lactulose I.S. (353/167),
rhamnose analyte (163/58.8). The rhamnose analyte
was quantified using the mannitol I.S. Mannitol, lactu-
lose and rhamnose were used to make the standard
curves and the sources for the internal standard were
purchased from Sigma-Aldrich (St. Louis, Missouri,
USA). Analytical validation of the assay is included in
online supplementary materials.
Statistical analysis
Patient characteristics within each population were sum-
marised using the median and range for continuous mea-
sures. Categorical measures were summarised as counts
and percentages. Fractional recovery of rhamnose and
lactulose levels across the three cohorts was assessed
using the Kruskal-Wallis test. Post-dosing concentrations
of rhamnose and lactulose as well as the lactulose: rham-
nose ratio (LRR) and anthropomorphic measures were
compared in the three groups using the Kruskal-Wallis
test. Detectable urinary rhamnose (concentration
>1.0 µg/mL) in the post dosing urine specimen was
required to consider the test evaluable. The 95th centile
of the LRR in the US cohort was defined a priori as the
maximum for a normal, healthy population.
Weight-for-age Z scores (WAZ) and height-for-age Z
scores (HAZ) were compared with post-dose lactulose in
scatterplots showing the study cohort (symbol) and
quartile of post-dose rhamnose (colour). Linear regres-
sion was used to predict WAZ scores and HAZ scores
with post-dose lactulose, post-dose rhamnose and the
interaction of these two predictors in two separate
models. All analyses were performed using the SAS soft-
ware (V.9.4, SAS Institute, Cary, North Carolina, USA).
Sample size calculation
The coefficient of variation for the assay of Mannitol
and Lactulose in adult healthy participants is 33% and
50%, respectively. Detectable difference with n=12 per
group (eg, healthy vs EED) would have 80% power to
detect a difference in rhamnose excretion of 40% and
in lactulose excretion of 58%. These predictions were
based on a >600% increase in L:M ratio in Crohn’s
disease (0.054±0.060 in health vs 0.323±0.253 in Crohn’s
disease).10 Furthermore, in irritable bowel syndrome
(IBS), which is typically associated with diarrhoea, there
is at least a twofold increase in small intestinal perme-
ability relative to controls and IBS associated with consti-
pation; small intestinal permeability was increased in IBS
(0.19 (0.12–0.23)) in contrast to constipated IBS (0.085
(0.043–0.13)) and controls (0.07 (0.035–0.19)).11
RESULTS
Subject demographics
The age and anthropometric data including median
height/length and weight-for-age z-scores (HAZ and
WAZ, respectively) of the three cohorts are included in
table 1. Children from Peru (n=19) and Zambia (n=85)
were older when compared to the US healthy popula-
tion (n=27). Median (range) WAZ and HAZ in the
Peruvian cohort (WAZ: −0.8 (−2.7, 0.8); HAZ: −1.8
(−3.3, −0.2)) and the Zambian cohort (WAZ: −1.4
(−4.0, 1.1); HAZ: −2.3 (−8.5, 1.2)) were significantly dif-
ferent from that in the US cohort (WAZ: 0.5 (−0.4, 2.1),
p<0.001; HAZ: −0.1 (−1.8, 2.4), p<0.001, table 1). Thus,
while the cohorts of children from regions endemic for
EED were not overtly ill, anthropometric indices sug-
gested that they were representative of affected children
with EED in these populations.
Feasibility of urine saccharide absorption test
The infants from all three cohorts followed the standard
protocol of sugar administration (see methods).
Evaluable tests were seen in 22/27 US infants (81%),
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19/19 Peruvian children (100%) and 73/85 Zambian
children (86%). In the US cohort, regurgitation of sac-
charide solution or urine collection bag failure (leak)
was the primary cause of test failure (5 cases compared
to 22 successful test applications). Similar metadata was
not available from Zambia to determine the primary
causes of test failure. The median (range) of total urine
volume collected (mL) was 13.4 (1.3, 65.1), 21.5 (7.0,
67.0) and 5.0 (0.5, 10.0) in the US, Peruvian and
Zambian cohorts, respectively.
Baseline urinary levels of mannitol
Detectable concentrations of mannitol were present in
over 90% of children in all three cohorts within the
baseline urine sample. Since these samples were col-
lected prior to saccharide dosing (and mannitol was not
used as a probe), this finding indicates significant envir-
onmental contamination. The median (range) of the
mannitol concentration identified prior to saccharide
dosing in the cohorts from the USA, Peru and Zambia
was 5.2 µg/mL (0.1, 17.3), 10.8 µg/mL (0.0, 29.7) and
10.3 µg/mL (0.8, 40.2), respectively (table 2). We
assessed pre-dosed (baseline) urine samples for the pres-
ence of L-rhamnose. In all three cohorts, the presence
of L-rhamnose in pre-administration urine was negligible
(table 2). Indeed, there were only 3 individuals (2.6%)
in the entire cohort who had pre-dosing urine levels of
rhamnose and lactulose that theoretically could inter-
fere with the interpretation of the assay results.
Permeability measurements using fractional excretion of
saccharides and lactulose: rhamnose ratio in participants
at risk for EED
Rhamnose excretion: There were no significant differ-
ences in the permeability to rhamnose as assessed by
median urinary rhamnose concentrations between the
three groups (table 3, figure 1). The fractional recovery
of rhamnose was significantly higher in the US (0.38%
(0.00%, 1.84%)) and Peruvian (0.61% (0.02%, 6.32%))
cohorts compared to the Zambian (0.07% (0.00%,
1.50%)) cohort (p<0.001) (table 3).
Lactulose excretion: Significant differences in lactu-
lose as expressed by both urine concentrations and frac-
tional excretion were evident in the cohorts of patients
from areas endemic for EED compared to the US con-
trols (table 3, figure 1). Consistent with the lack of sig-
nificant pre-dosing saccharide contamination (table 2),
results were identical on analysis of δ lactulose (post-
dose lactulose less pre-dose concentration, data not
shown). Similar to the lactulose concentration, the frac-
tional recovery of lactulose was significantly greater in
the Zambian (0.03% (0.00%, 0.35%)) and Peruvian
(0.15% (0.01%, 0.69%) cohorts when compared to the
US (0.01% (0.00%, 0.07%)) cohort (p<0.001, table 3).
Lactulose to rhamnose ratio: Given the previous
experience with saccharide ratios and the challenges of
urine bag collection with precise urine volume record-
ing in the field, we calculated the lactulose to rhamnose
ratio based on concentrations of the sugars (LRR). We
observed significant differences in the median (range)
LRR in the Peruvian (0.75 (0.15, 5.02)) and Zambian
(2.26 (0.08, 14.48)) cohorts compared to the US (0.14
(0.06, 1.00)) cohort (p<0.001) (table 3, figure 1). Using
the 95th centile from the US population as the upper
limit of normal, ∼53% of Peruvian children and 82% of
Zambian children studied displayed abnormal LRR
(p<0.001, table 3).
Appraisal of height and weight relative to LRR
Using the HAZ and WAZ scores of children at the time
of LRR within the Zambian and Peruvian cohorts, we
assessed the ability of WAZ and HAZ to predict
Table 1 Demographic characteristics for the study cohorts from the USA, Peru and Zambia
USA (N=27) Peru (N=19) Zambia* (N=85)
Age (months), median (range) 8.0 (2.0 to 13.0) 27.0 (15.0 to 29.0) 21.0 (12.0 to 36.0)
Gender, N (%)
F 8 (30) 8 (42) 45 (63)
M 19 (70) 11 (58) 27 (38)
Height-for-age z-score, median (range) −0.1 (−1.8 to 2.4) −1.8 (−3.3 to −0.2) −2.3 (−8.5 to 1.2)
Weight-for-age z-score, median (range) 0.5 (−0.4 to 2.1) −0.8 (−2.7 to 0.8) −1.4 (−4.0 to 1.1)
δ Rhamnose <1 N (%) 5 (19) 0 (0) 12 (14)
*In the Zambian cohort, age was available on 73 participants while gender and z-scores were available on 72 participants.
Table 2 Median (range) of pre-dosing sugar concentrations by study cohort
USA (N=20)* Peru (N=19) Zambia (N=63)* p Value†
Pre-mannitol (μg/mL) 5.2 (0.1 to 17.3) 10.8 (0.0 to 29.7) 10.3 (0.8 to 40.2) 0.046
Pre-rhamnose (μg/mL) 0.0 (0.0 to 0.4) 0.0 (0.0 to 20.1) 0.1 (0.0 to 36.9) 0.024
Pre-lactulose (μg/mL) 0.0 (0.0 to 4.0) 0.5 (0.0 to 19.9) 0.1 (0.0 to 86.1) 0.043
*Pre-dosing sugar data for the U.S. cohort was available for 20 of the 27 participants and for the Zambian cohort in 63 of the 85 participants.
†Kruskal-Wallis test.
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abnormal LRR as defined by >95%centile in the US
cohort (figure 2). In a multivariate effect modification
model in which the outcome was WAZ score (table 4),
lower post-dose lactulose was associated with higher WAZ
scores among children with the same level of post-dose
rhamnose (p=0.0002). When children differed in rham-
nose, however, those with both higher rhamnose and
higher lactulose also had slightly greater WAZ scores
(p=0.01) after accounting for the association between
lactulose and weight for age when rhamnose was the
same. In this model, 13% of the WAZ score variability
among children was explained by lactulose and rham-
nose excretion. A similar pattern emerged when predict-
ing height-for-age Z scores, but the differences were not
statistically significant.
DISCUSSION
EED results from the chronic inflammatory response to
repetitive GI infectious insults, and thus populations
living in poverty in the developing world are commonly
affected to varying degrees. A general association of the
lactulose to mannitol ratio, particularly in relationship to
impaired linear growth, has been noted among several
groups; however, significant issues remain with the test’s
performance.5 We provide normative values of the lactu-
lose/rhamnose permeability assay in healthy infants and
document evidence for increased intestinal permeability
in two cohorts of children from populations in which
EED is endemic. These observations suggest that the
method described has the potential to provide consist-
ent test performance in the field for the detection of
Table 3 Summary of sugar excretion following oral administration by study cohort
Summary of sugar excretion following oral administration by population
USA (N=22) Peru* (N=19) Zambia† (N=73) p Value
Post-rhamnose (ug/mL), median (range) 50.10 (0.29 to 213.00) 102.00 (2.66 to 301.00) 34.50 (1.58 to 847.00) 0.354‡
Fractional recovery rhamnose (%),
median (range)
0.38 (0.00 to 1.84) 0.61 (0.02 to 6.32) 0.07 (0.00 to 1.50) 0<0.001‡
Post-lactulose (μg/mL), median (range) 6.78 (0.29 to 31.90) 47.60 (4.23 to 379.00) 75.40 (0.67 to 873.00) <0.001‡
Fractional recovery lactulose (%),
median (range)
0.01 (0.00 to 0.07) 0.15 (0.01 to 0.69) 0.03 (0.00 to 0.35) <0.001‡
LR ratio, median (range) 0.14 (0.06 to 1.00) 0.75 (0.15 to 5.02) 2.26 (0.08 to 14.48) <0.001‡
Abnormal post LRR compared to the
American 95th centile
1 (5%) 10 (53%) 60 (82%) <0.001§
*Fractional recovery was available in 18 of the 19 Peruvian participants.




Figure 1 Box plot comparison of pre-dose and post-dose concentrations for rhamnose and lactulose for the three study
cohorts.
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impaired intestinal barrier integrity in EED. Our data
also suggest that there was monosaccharide (rhamnose)
malabsorption (reduced absolute mass excreted and
fractional recovery in urine) in at-risk children from
Zambia compared to US controls, and that the stunted
weight observed in the at-risk cohorts was associated
with the documented measurements of monosaccharide
malabsorption as well as increased intestinal permeabil-
ity, which is best adjudicated on the basis of the lactulose
excretion, fractional recovery of lactulose in urine and
LRR. Thus, children in Zambia have evidence for both
monosaccharide malabsorption and increased intestinal
permeability to the larger disaccharide molecule.
Current understanding is consistent with the existence
of two pore sizes in the human small intestinal epithe-
lium, with the larger pore size (10.1 Angstrom) present
in the crypts while the smaller pores are located in the
villus tip.12 In extensive small intestinal diseases asso-
ciated with significant flattening of the villus border and
resultant impairment of the surface area, it is not clear
whether paracellular transport through either pore is
proportionally affected and the overall effect of
decreased surface area is also unclear. We observed a sig-
nificantly lower recovery of the monosaccharide rham-
nose in the cohort of children from Zambia when
compared to the US and Peruvian cohorts. Similarly, low
recovery of the monosaccharide mannitol was described
in affected children in Gambia, suggesting the significant
contribution of malabsorption along with altered perme-
ability in the interpretation of saccharide permeability
assays in severely affected children.13 Combinatorial
effects of malabsorption and altered permeability are
general limitations in assessment of solute trafficking
dependent on size. Indeed, the impact of mannitol excre-
tion in driving variances in LMR across studies has been
previously postulated.14 We speculate that the diminished
recovery of rhamnose in the Zambian cohort reflects
decreased intestinal surface area related to villus blunting
and a more severe phenotype, and this may compromise
the assessment of the ratio of excretion of the two sac-
charides in the LRR. Therefore, the absolute excretion
or fractional recovery of the disaccharide alone may
potentially be a more accurate marker of intestinal per-
meability. Overall, these data emphasise the importance
of separate reporting of recovery for both saccharides.
Our data suggest the growth stunting evident in the
at-risk cohorts to be associated with impaired intestinal
permeability as evidenced by the coefficient of deter-
mination (R2) of the multivariate regression model to
predict weight-for-age and height-for-age z scores. One
factor contributing to improved assay concordance may
be the timing of urine collection. The simultaneous
assessment of intestinal transit and lactulose and manni-
tol permeability in healthy adult participants indicates
Figure 2 Scatterplot weight-for-age Z scores (WAZ) and height-for-age Z scores (HAZ) by post-dose lactulose and rhamnose
concentration for the three study cohorts.
Table 4 Linear regression results predicting weight-for-age and height-for-age Z scores by post-dose lactulose and rhamnose
concentrations and their interaction
Outcome variable Predictor Coefficient (95% CI) p Value R2
Weight-for-age Z score (N=104) Intercept −0.5007 (−0.9248 to 0.01766) 0.003 13%
Post lactulose −0.0041 (−0.0063 to −0.002) <0.001
Post rhamnose −0.0007 (−0.0033 to 0.0017) 0.536
Lactulose-rhamnose interaction 0.000007 (0.00000 to 0.00001) 0.013
Height-for-age Z score (N=104) Intercept −1.13512 (−1.5629 to −0.7075) <0.001 10%
Post lactulose −0.0046 (−0.0074 to −0.0018) 0.0018
Post rhamnose −0.0008 (−0.0041 to 0.0025) 0.630
Lactulose-rhamnose interaction 0.000007 (−0.00000 to 0.00002) 0.098
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that urine collection within 2 hours of oral sugar load
reflects primarily small intestinal permeability while col-
lection beyond 8 hours reflects exclusively colonic
absorption.7 While equivalent data are not available in
children, previous protocols have uniformly extended
the collection to 5 hours during which the saccharide
can reach the caecum and ascending colon in at least a
subset of participants;15–36 thus, such recovery studies
may have assessed both small bowel and colonic perme-
ability with interindividual variances related to the differ-
ences in location of the saccharides during the 5 hours
of urine collection.
Finally, the regression analyses show that permeability
is a marker that alone accounts for ∼13% of the vari-
ance in WAZ. Thus, other factors such as malabsorption,
recurrent infection and undernutrition constitute other
risk factors that most likely contribute to the low WAZ
and HAZ. Nevertheless, permeability measurement con-
stitutes a good screening test for EED in the field, and
should lead to a search for concomitant risk factors or
institution of interventions to restore barrier integrity,
when such drugs become available.
In conclusion, we demonstrate a novel method that
refines the saccharide intestinal permeability assay. The
advantages of the method that we have applied in the
field in Zambia and Peru are decreased dose of sacchar-
ides administered, shortened urine collection time and
use of a monosaccharide without risk of significant envir-
onmental contamination. Minimal environmental con-
tamination may lead to the lack of reliance on baseline
urine samples; yet further validation with corresponding
histology in a separate disease cohort (coeliac disease) is
currently ongoing.
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